Teladoc buys mental health company UpLift to help boost struggling BetterHelp unit

Teladoc buys mental health company UpLift to help boost struggling BetterHelp unit


Teladoc Health Inc. signage on the floor of the New York Stock Exchange on Dec. 31, 2024.

Michael Nagle | Bloomberg | Getty Images

Virtual care provider Teladoc Health, which has seen its market value plummet over the past five years, said Wednesday that it acquired mental health company UpLift for $30 million in cash.

Teladoc said the acquisition will help the company build out its struggling BetterHelp mental health segment. Revenue at BetterHelp declined 10% to about $250 million in 2024, and has faced challenges since the economy started reopening after the Covid pandemic.

UpLift, which offers virtual mental health therapy, psychiatry and medication management services, generated around $15 million in revenue last year, Teladoc said.  

“BetterHelp was founded to remove the traditional barriers to therapy and make mental health care more accessible to everyone,” BetterHelp President Fernando Madeira said in a statement. “We believe joining forces with UpLift will help us advance that mission — especially for those seeking to use their coverage benefits — while also driving topline revenue growth that will help sustain and expand our impact over time.”

Teladoc said the deal closed Wednesday, and UpLift will be factored into the BetterHelp segment going forward.

Don’t miss these insights from CNBC PRO

Shares of Teladoc fell more than 2% in extended trading. The company also announced its first-quarter results after market close, reporting revenue of $629.4 million, down 3% year-over-year. Teladoc reported a net loss of $93.0 million, or a 53-cent loss per share.

The UpLift acquisition comes two months after Teladoc announced plans to buy preventative care company Catapult Health, which offers an at-home wellness exam, for $65 million.

Teladoc CEO Chuck Divita has been working to turn the company around after four-straight quarters of declining revenue and an extended slump in the stock price. When Teladoc acquired digital health company Livongo in 2020, it had a combined enterprise value of $37 billion. In early 2022, Teladoc took a write-down of about $6.6 billion tied to the Livongo deal.

Teladoc now has a market capitalization of just over $1 billion. The stock has fallen about 20% this year.

WATCH: Interview with Teladoc CEO

Teladoc Health CEO Jason Gorevic on positive Q1 earnings results



Source

RFK Jr.’s firing of CDC vaccine panel undermines science, could threaten public health, experts say
Health

RFK Jr.’s firing of CDC vaccine panel undermines science, could threaten public health, experts say

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. leaves the stage after discussing the findings of the Centers for Disease Control and Prevention’s (CDC) latest Autism and Developmental Disabilities Monitoring (ADDM) Network survey, at the Department of Health and Human Services in Washington, D.C., U.S., April 16, 2025. Elizabeth Frantz | Reuters […]

Read More
RFK Jr. removes all members of CDC panel advising U.S. on vaccines
Health

RFK Jr. removes all members of CDC panel advising U.S. on vaccines

U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. testifies before the Senate Committee on Appropriations hearing on the Department of Health and Human Services budget, on Capitol Hill in Washington, D.C., U.S., May 20, 2025. Ken Cedeno | Reuters Health and Human Services Secretary Robert F. Kennedy Jr. on Monday said he […]

Read More
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Health

FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca

The Food and Drug Administration on Monday approved Merck’s shot designed to protect infants from respiratory syncytial virus during their first season of the virus, bringing to market a rival to a similar treatment from Sanofi and AstraZeneca. The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead […]

Read More